- Home
- HBT vs MGTX Comparison
HBT vs MGTX Comparison
Compare HBT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | MGTX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.3M | 909.1M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HBT | MGTX |
|---|---|---|
| Price | $27.64 | $9.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $30.75 | $24.57 |
| AVG Volume (30 Days) | 65.1K | ★ 630.4K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 7.96 | ★ 33.02 |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $35.73 | $141.38 |
| Revenue Next Year | $7.01 | N/A |
| P/E Ratio | $79.53 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $22.36 | $5.02 |
| 52 Week High | $29.88 | $11.85 |
Technical Indicators
Market Signals| Indicator | HBT | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 48.12 |
| Support Level | $27.36 | $7.13 |
| Resistance Level | $27.85 | $9.65 |
| Average True Range (ATR) | 0.62 | 0.48 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 30.95 | 42.57 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.